Editorial: Pathogenesis, treatment, and future directions for rare T-cell leukemias

Front Oncol. 2022 Sep 7:12:991527. doi: 10.3389/fonc.2022.991527. eCollection 2022.

Marco Herling^{1

2}, Wael Jarjour³, Anjali Mishra⁴, Jonathan E Brammer⁵

¹ Department of Hematology, Cellular Therapy, and Hemostasis University of Leipzig, Leipzig, Germany.
² Department of Internal Medicine, Center for Integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Duesseldorf, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne (UoC), Cologne, Germany.
³ Division of Rheumatology, The Ohio State University, Columbus, OH, United States.
⁴ Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology and Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
⁵ Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.

No abstract available

Keywords: IL-15; Mature T-cell leukemia; T-cell leukemia; T-prolymphocytic leukemia; cytokine; large granular lymphocyte (LGL) leukemia.

Publication types